- Home
- / TESARO
TESARO
Revenue
$223.3 M
FY, 2017
TESARO Summary
Company Summary
- Overview
- TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. It develops rolapitant, a potent, selective neurokinin-1 receptor antagonist that can be used for the prevention of chemotherapy-induced nausea and vomiting. The company advances its ALK inhibitor program for oncology indications.
- Type
- Subsidiary
- Status
- Closed
- Founded
- 2010
- HQ
- Waltham, MA, US | view all locations
- Website
- http://www.tesarobio.com/
- Cybersecurity rating
Table of Contents
Key People
William Aitchison, Senior Vice President, Technical Operations
Greg Covino, Senior Vice President, Chief Accounting Officer
Allene Diaz, Senior Vice President, Global Commercial Development and Program Strategy
Operating MetricsView all
Products
2
FY, 2016
Countries
7
FY, 2016
Patent Portfolios
3
FY, 2016
LocationsView all
8 locations detected
Waltham, MA HQ
United States
1000 Winter St
Wien, Wien
Austria
Fleischmarkt 1
Boulogne-Billancourt, Île-de-France
France
235 Avenue le Jour Se Lève
München, BY
Germany
Leopoldstraße 37a
Roma, Lazio
Italy
Via Vincenzo Bellini, 22
Madrid, Comunidad de Madrid
Spain
Camino de la Zarzuela, 19, 1ºC
TESARO Financials
Summary Financials
- Revenue (Q3, 2018)
- $64.4M
- Gross profit (Q3, 2018)
- $50.2M
- Net income (Q3, 2018)
- ($137.1M)
- Cash (Q3, 2018)
- $476.8M
- EBIT (Q3, 2018)
- ($138.2M)